Hepatitis B Virus Reactivation Potentiated by Biologics.

[1]  Anh-Hoa Nguyen,et al.  Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study. , 2019, Journal of hepatology.

[2]  S. Ferrone,et al.  In vitro elimination of epidermal growth factor receptor‐overexpressing cancer cells by CD32A‐chimeric receptor T cells in combination with cetuximab or panitumumab , 2019, International journal of cancer.

[3]  J. Shih,et al.  Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. , 2019, European journal of cancer.

[4]  S. Ferrone,et al.  Elimination of Egfr-Overexpressing Cancer Cells by CD32 Chimeric Receptor T Cells in Combination with Cetuximab or Panitumumab , 2019, bioRxiv.

[5]  A. Lok,et al.  Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long‐term Treatment With Tumor Necrosis Factor Antagonists , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  R. Hui,et al.  Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. , 2018, Acta dermato-venereologica.

[7]  S. Deresinski,et al.  Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management , 2018, Open forum infectious diseases.

[8]  W. Seto,et al.  Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment , 2018, Annals of Hematology.

[9]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[10]  G. Ippolito,et al.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  C. La Motta,et al.  Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. , 2018, Oncology reports.

[12]  N. Kröger,et al.  Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved? , 2018, Blood.

[13]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[14]  Pei-Jer Chen,et al.  Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. , 2017, Gastroenterology.

[15]  N. Furusyo,et al.  Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy , 2017, Drug design, development and therapy.

[16]  Yao-Chun Hsu,et al.  Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics , 2017, Expert review of gastroenterology & hepatology.

[17]  Adam C Lake.  Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy. , 2017, AIDS.

[18]  F. Cominelli,et al.  Natalizumab in the treatment of Crohn’s disease patients , 2017, Expert opinion on biological therapy.

[19]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[20]  G. Lau,et al.  Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta‐analysis , 2017, Hepatology.

[21]  T. Hsieh,et al.  Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study , 2017, Annals of the rheumatic diseases.

[22]  E. Deeks,et al.  Abatacept: A Review in Rheumatoid Arthritis , 2017, Drugs.

[23]  Cheng-Shyong Chang,et al.  Hepatitis B reactivation in patients receiving targeted therapies , 2017, Hematology.

[24]  T. Liang,et al.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. , 2017, Gastroenterology.

[25]  T. Waldmann,et al.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. , 2017, Annual review of immunology.

[26]  T. Wyant,et al.  An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. , 2016, Journal of Crohn's & colitis.

[27]  M. Iwamoto,et al.  Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease‐modifying antirheumatic drugs , 2016, International journal of rheumatic diseases.

[28]  L. Rostaing,et al.  Belatacept and Long-Term Outcomes in Kidney Transplantation. , 2016, The New England journal of medicine.

[29]  Fares Alahdab,et al.  Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis , 2016, Hepatology.

[30]  C. Gabay,et al.  The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases. , 2015, Cytokine.

[31]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[32]  S. Mori,et al.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. , 2015, World journal of gastroenterology.

[33]  M. Barone,et al.  Safety of long‐term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection , 2015, Hepatology.

[34]  E. Gunduz,et al.  Hepatitis B Virus Reactivation under Treatment with Nilotinib , 2015, Euroasian journal of hepato-gastroenterology.

[35]  F. Anania,et al.  Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  J. Smolen,et al.  A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate , 2015, Annals of the rheumatic diseases.

[37]  C. Hunter,et al.  IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.

[38]  R. Advani,et al.  Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.

[39]  Jiyuan Zhang,et al.  Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients , 2015, Cellular and Molecular Immunology.

[40]  S. Cook,et al.  Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[41]  M. Yuen,et al.  Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Boccia,et al.  HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis , 2014, International journal of rheumatology.

[43]  P. Schneider,et al.  The BAFF/APRIL system in SLE pathogenesis , 2014, Nature Reviews Rheumatology.

[44]  Yi-yang Chen,et al.  Hepatitis B virus reactivation associated with ruxolitinib , 2014, Annals of Hematology.

[45]  A. Moorman,et al.  Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[46]  A. Lok,et al.  Management of patients with hepatitis B who require immunosuppressive therapy , 2014, Nature Reviews Gastroenterology &Hepatology.

[47]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[48]  Yiqi Yu,et al.  Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy—a report of long-term follow-up of serial cases and literature review , 2013, Clinical Rheumatology.

[49]  T. Tsai,et al.  The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C , 2013, The British journal of dermatology.

[50]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[51]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[52]  B. Rehermann.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells , 2013, Nature Medicine.

[53]  J. Koskinas,et al.  Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface‐antigen‐negative anti‐HBs‐positive patient , 2013, The British journal of dermatology.

[54]  M. Massari,et al.  Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. , 2012, Gastroenterology.

[55]  Kelvin K. W. Chan,et al.  Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  D. Furst,et al.  Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B , 2012, Arthritis care & research.

[57]  B. Ni,et al.  Pivotal roles of the interleukin‐23/T helper 17 cell axis in hepatitis B , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[58]  L. López-Rosés,et al.  Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy: Analysis of 257 Cases , 2011, Medicine.

[59]  E. Keeffe,et al.  Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection , 2011, Hepatology.

[60]  S. Belknap,et al.  Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  K. Buchacz,et al.  Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996–2007 † , 2010, Journal of viral hepatitis.

[62]  Lewis R. Roberts,et al.  Hepatocellular carcinoma: a global view , 2010, Nature Reviews Gastroenterology &Hepatology.

[63]  E. Bini,et al.  Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions , 2010, Hepatology.

[64]  Y. Chae,et al.  Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review , 2009, International journal of hematology.

[65]  J. Hoofnagle,et al.  Reactivation of hepatitis B , 2009, Hepatology.

[66]  K. Wittkowski,et al.  Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis , 2007, Journal of Translational Medicine.

[67]  G. Freeman,et al.  PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver1 , 2007, The Journal of Immunology.

[68]  F. Chisari,et al.  Immunobiology and pathogenesis of viral hepatitis. , 2006, Annual review of pathology.

[69]  H. Ohira,et al.  Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment , 2006, Leukemia & lymphoma.

[70]  D. Douek,et al.  Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. , 2005, Blood.

[71]  E. Iannitto,et al.  Hepatitis B virus reactivation and alemtuzumab therapy , 2005, European journal of haematology.

[72]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[73]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[74]  M. Manns,et al.  Structural organization of the hepatitis B virus minichromosome. , 2001, Journal of molecular biology.

[75]  R. Perrillo.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. , 2001, Gastroenterology.

[76]  C. Seeger,et al.  Hepatitis B Virus Biology , 2000, Microbiology and Molecular Biology Reviews.

[77]  B. Chapman,et al.  Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  F. Sánchez‐Madrid,et al.  Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis , 1994, The Journal of experimental medicine.

[79]  J. Hoofnagle,et al.  Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B , 1993, Hepatology.

[80]  L. Puig.  Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others. , 2018, Current problems in dermatology.

[81]  L. Sepiashvili,et al.  Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. , 2016, Advances in clinical chemistry.

[82]  Y. Falck‐Ytter,et al.  American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy , 2014 .

[83]  S. Bae,et al.  Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. , 2013, Clinical and experimental rheumatology.

[84]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. , 2012, eLife.

[85]  E. Concia,et al.  Failure of lamivudine therapy for chemotherapy-induced reactivation of Hepatitis B , 2001, American Journal of Gastroenterology.

[86]  E. Keeffe,et al.  Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection , 1999, American Journal of Gastroenterology.

[87]  F. Chisari,et al.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. , 1996, Immunity.

[88]  A. Lok,et al.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .